STERIS plc (STE)
USD 206.9
(-2.75%)
USD 206.9
(-2.75%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 3.12 Billion USD | 3.36% |
| 2023 | 3.01 Billion USD | 2.48% |
| 2022 | 2.94 Billion USD | 78.46% |
| 2021 | 1.65 Billion USD | 43.46% |
| 2020 | 1.15 Billion USD | -2.76% |
| 2019 | 1.18 Billion USD | -10.09% |
| 2018 | 1.31 Billion USD | -10.98% |
| 2017 | 1.47 Billion USD | -5.7% |
| 2016 | 1.56 Billion USD | 151.55% |
| 2015 | 623.25 Million USD | 26.3% |
| 2014 | 493.48 Million USD | 0.24% |
| 2013 | 492.29 Million USD | 134.42% |
| 2012 | 210 Million USD | 0.0% |
| 2011 | 210 Million USD | 0.0% |
| 2010 | 210 Million USD | 0.0% |
| 2009 | 210 Million USD | 17.14% |
| 2008 | 179.28 Million USD | 77.86% |
| 2007 | 100.8 Million USD | -11.95% |
| 2006 | 114.48 Million USD | 9.79% |
| 2005 | 104.27 Million USD | -4.41% |
| 2004 | 109.09 Million USD | 82.72% |
| 2003 | 59.7 Million USD | -48.19% |
| 2002 | 115.22 Million USD | -44.02% |
| 2001 | 205.82 Million USD | -23.4% |
| 2000 | 268.7 Million USD | 21.31% |
| 1999 | 221.5 Million USD | 44.89% |
| 1998 | 152.87 Million USD | 325.85% |
| 1997 | 35.9 Million USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | -100.0% |
| 1991 | 400 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 3.39 Billion USD | -4.02% |
| 2024 Q1 | 2.86 Billion USD | -5.25% |
| 2024 Q2 | 3.36 Billion USD | 17.7% |
| 2024 Q4 | 3.12 Billion USD | -3.43% |
| 2024 FY | 3.12 Billion USD | 3.36% |
| 2023 Q3 | 3 Billion USD | -0.52% |
| 2023 FY | 3.01 Billion USD | 2.48% |
| 2023 Q4 | 3.01 Billion USD | 0.57% |
| 2023 Q2 | 3.01 Billion USD | 6.01% |
| 2023 Q1 | 2.84 Billion USD | -3.36% |
| 2022 Q4 | 2.94 Billion USD | -7.24% |
| 2022 Q2 | 3.42 Billion USD | -0.19% |
| 2022 Q1 | 3.42 Billion USD | 107.69% |
| 2022 FY | 2.94 Billion USD | 78.46% |
| 2022 Q3 | 3.17 Billion USD | -7.2% |
| 2021 FY | 1.65 Billion USD | 43.46% |
| 2021 Q3 | 1.71 Billion USD | 67.87% |
| 2021 Q4 | 1.65 Billion USD | -3.66% |
| 2021 Q1 | 1.02 Billion USD | -11.16% |
| 2021 Q2 | 1.02 Billion USD | -0.16% |
| 2020 Q3 | 1.24 Billion USD | 4.53% |
| 2020 Q2 | 1.18 Billion USD | -1.88% |
| 2020 Q1 | 1.21 Billion USD | 2.26% |
| 2020 Q4 | 1.15 Billion USD | -7.29% |
| 2020 FY | 1.15 Billion USD | -2.76% |
| 2019 Q1 | 1.32 Billion USD | 0.31% |
| 2019 Q4 | 1.18 Billion USD | -5.06% |
| 2019 FY | 1.18 Billion USD | -10.09% |
| 2019 Q2 | 1.26 Billion USD | -3.97% |
| 2019 Q3 | 1.24 Billion USD | -1.69% |
| 2018 Q1 | 1.49 Billion USD | 1.22% |
| 2018 Q3 | 1.42 Billion USD | -1.75% |
| 2018 Q4 | 1.31 Billion USD | -7.33% |
| 2018 FY | 1.31 Billion USD | -10.98% |
| 2018 Q2 | 1.44 Billion USD | -3.42% |
| 2017 Q1 | 1.55 Billion USD | -1.02% |
| 2017 Q3 | 1.5 Billion USD | 0.19% |
| 2017 Q4 | 1.47 Billion USD | -1.9% |
| 2017 FY | 1.47 Billion USD | -5.7% |
| 2017 Q2 | 1.5 Billion USD | -3.07% |
| 2016 Q2 | 829.81 Million USD | 20.94% |
| 2016 Q1 | 686.16 Million USD | 10.09% |
| 2016 Q3 | 1.63 Billion USD | 97.57% |
| 2016 Q4 | 1.56 Billion USD | -4.37% |
| 2016 FY | 1.56 Billion USD | 151.55% |
| 2015 Q2 | 619.95 Million USD | -5.89% |
| 2015 FY | 623.25 Million USD | 26.3% |
| 2015 Q1 | 658.74 Million USD | 33.49% |
| 2015 Q4 | 623.25 Million USD | 2.06% |
| 2015 Q3 | 610.68 Million USD | -1.5% |
| 2014 Q3 | 474.74 Million USD | -6.64% |
| 2014 Q2 | 508.52 Million USD | -1.01% |
| 2014 Q4 | 493.48 Million USD | 3.95% |
| 2014 Q1 | 513.7 Million USD | 4.35% |
| 2014 FY | 493.48 Million USD | 0.24% |
| 2013 Q2 | 434.34 Million USD | 106.83% |
| 2013 FY | 492.29 Million USD | 134.42% |
| 2013 Q3 | 520.89 Million USD | 19.93% |
| 2013 Q4 | 492.29 Million USD | -5.49% |
| 2013 Q1 | 210 Million USD | 0.0% |
| 2012 FY | 210 Million USD | 0.0% |
| 2012 Q4 | 210 Million USD | 0.0% |
| 2012 Q3 | 210 Million USD | 0.0% |
| 2012 Q2 | 210 Million USD | 0.0% |
| 2012 Q1 | 210 Million USD | 0.0% |
| 2011 Q3 | 210 Million USD | 0.0% |
| 2011 FY | 210 Million USD | 0.0% |
| 2011 Q1 | 210 Million USD | 0.0% |
| 2011 Q2 | 210 Million USD | 0.0% |
| 2011 Q4 | 210 Million USD | 0.0% |
| 2010 Q2 | 210 Million USD | 0.0% |
| 2010 FY | 210 Million USD | 0.0% |
| 2010 Q4 | 210 Million USD | -32.26% |
| 2010 Q3 | 310 Million USD | 47.62% |
| 2010 Q1 | 210 Million USD | 0.0% |
| 2009 Q3 | 210 Million USD | -16.0% |
| 2009 Q1 | 177.46 Million USD | -1.02% |
| 2009 FY | 210 Million USD | 17.14% |
| 2009 Q4 | 210 Million USD | 0.0% |
| 2009 Q2 | 250 Million USD | 40.88% |
| 2008 FY | 179.28 Million USD | 77.86% |
| 2008 Q1 | 109.78 Million USD | 8.91% |
| 2008 Q2 | 124.89 Million USD | 13.76% |
| 2008 Q3 | 132.22 Million USD | 5.87% |
| 2008 Q4 | 179.28 Million USD | 35.59% |
| 2007 Q1 | 188.14 Million USD | 64.34% |
| 2007 FY | 100.8 Million USD | -11.95% |
| 2007 Q4 | 100.8 Million USD | -19.63% |
| 2007 Q3 | 125.42 Million USD | -14.7% |
| 2007 Q2 | 147.03 Million USD | -21.85% |
| 2006 Q1 | 125.71 Million USD | 20.56% |
| 2006 Q4 | 114.48 Million USD | 9.38% |
| 2006 FY | 114.48 Million USD | 9.79% |
| 2006 Q3 | 104.65 Million USD | -0.95% |
| 2006 Q2 | 105.66 Million USD | -15.95% |
| 2005 Q3 | 103.43 Million USD | -3.13% |
| 2005 FY | 104.27 Million USD | -4.41% |
| 2005 Q1 | 104.58 Million USD | -4.13% |
| 2005 Q2 | 106.77 Million USD | 2.09% |
| 2005 Q4 | 104.27 Million USD | 0.81% |
| 2004 Q3 | 110.4 Million USD | 8.75% |
| 2004 FY | 109.09 Million USD | 82.72% |
| 2004 Q1 | 115.25 Million USD | 93.05% |
| 2004 Q2 | 101.52 Million USD | -11.92% |
| 2004 Q4 | 109.09 Million USD | -1.19% |
| 2003 Q2 | 100.31 Million USD | -3.95% |
| 2003 Q4 | 59.7 Million USD | -30.48% |
| 2003 Q1 | 104.44 Million USD | -9.36% |
| 2003 Q3 | 85.88 Million USD | -14.39% |
| 2003 FY | 59.7 Million USD | -48.19% |
| 2002 FY | 115.22 Million USD | -44.02% |
| 2002 Q4 | 115.22 Million USD | -21.01% |
| 2002 Q2 | 166.29 Million USD | -2.3% |
| 2002 Q3 | 145.87 Million USD | -12.28% |
| 2002 Q1 | 170.21 Million USD | -17.3% |
| 2001 Q3 | 220.2 Million USD | -13.88% |
| 2001 FY | 205.82 Million USD | -23.4% |
| 2001 Q4 | 205.82 Million USD | -6.53% |
| 2001 Q1 | 255.7 Million USD | -4.84% |
| 2001 Q2 | 255.7 Million USD | 0.0% |
| 2000 Q1 | 256.5 Million USD | 15.8% |
| 2000 Q4 | 268.7 Million USD | 1.05% |
| 2000 Q2 | 266.5 Million USD | 3.9% |
| 2000 FY | 268.7 Million USD | 21.31% |
| 2000 Q3 | 265.9 Million USD | -0.23% |
| 1999 Q2 | 202.3 Million USD | 32.35% |
| 1999 FY | 221.5 Million USD | 44.89% |
| 1999 Q1 | 152.85 Million USD | -0.02% |
| 1999 Q4 | 221.5 Million USD | 4.63% |
| 1999 Q3 | 211.7 Million USD | 4.65% |
| 1998 Q4 | 152.87 Million USD | -0.21% |
| 1998 Q1 | 35.85 Million USD | -0.13% |
| 1998 Q2 | 153.72 Million USD | 328.76% |
| 1998 Q3 | 153.2 Million USD | -0.34% |
| 1998 FY | 152.87 Million USD | 325.85% |
| 1997 Q1 | 43.1 Million USD | 0.0% |
| 1997 Q2 | - USD | -100.0% |
| 1997 Q3 | 43.1 Million USD | 0.0% |
| 1997 FY | 35.9 Million USD | 0.0% |
| 1997 Q4 | 35.9 Million USD | -16.71% |
| 1996 FY | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 Q2 | 500 Thousand USD | 0.0% |
| 1995 Q3 | - USD | -100.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 FY | - USD | -100.0% |
| 1991 Q4 | 400 Thousand USD | 0.0% |
| 1991 FY | 400 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott Laboratories | 13.59 Billion USD | 77.056% |
| Allurion Technologies Inc. | 2.3 Million USD | -135206.245% |
| Artivion, Inc. | 305.53 Million USD | -921.226% |
| Avanos Medical, Inc. | 159.4 Million USD | -1857.442% |
| Butterfly Network, Inc. | 22.83 Million USD | -13563.946% |
| Butterfly Network, Inc. | 22.83 Million USD | -13563.946% |
| Bio-Rad Laboratories, Inc. | 1.18 Billion USD | -162.319% |
| Boston Scientific Corporation | 8.96 Billion USD | 65.181% |
| CONMED Corporation | 971.48 Million USD | -221.175% |
| Edwards Lifesciences Corporation | 670 Million USD | -365.696% |
| Paragon 28, Inc. | 109.79 Million USD | -2741.703% |
| Glaukos Corporation | 383.73 Million USD | -713.097% |
| Globus Medical, Inc. | 417.4 Million USD | -647.523% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -12458.005% |
| Integer Holdings Corporation | 959.92 Million USD | -225.042% |
| Medtronic plc | 23.87 Billion USD | 86.932% |
| Myomo, Inc. | 115.16 Thousand USD | -2709314.727% |
| Nevro Corp. | 211.47 Million USD | -1375.456% |
| Owlet, Inc. | 22 Thousand USD | -14182454.545% |
| Penumbra, Inc. | 220.9 Million USD | -1312.42% |
| Vicarious Surgical Inc. | 13.78 Million USD | -22534.472% |
| Smith & Nephew plc | 2.17 Billion USD | -43.456% |
| Sonendo, Inc. | 14.03 Million USD | -22131.293% |
| Stryker Corporation | 10.9 Billion USD | 71.377% |
| Vapotherm, Inc. | 109.97 Million USD | -2737.078% |
| Zimmer Biomet Holdings, Inc. | 4.86 Billion USD | 35.903% |